Table 1.
Osteoprotegerin genotype frequencies in prostate cancer patients (PCa) and control males
| 149 T/C | |||||
| 149 T/C Genotype | C allele frequency (%) | ||||
| Study group | Total no. | CC | TC | TT | |
| PCaa | 361 | 4 (1.1) | 84 (23.3) | 273 (75.6) | 12.742 |
| Stageb | |||||
| A | 24 | 1 (4.2) | 5 (20.8) | 18 (75.0) | 14.583 |
| B | 184 | 1 (0.5) | 40 (21.7) | 143 (77.8) | 11.413 |
| C | 56 | 1 (1.8) | 16 (28.6) | 39 (69.6) | 16.071 |
| D | 97 | 1 (1.0) | 23 (23.7) | 73 (75.3) | 12.886 |
| Organ confined PCa | 208 | 2 (1.0) | 45 (21.6) | 161 (77.4) | 11.778 |
| Extraprostatic PCa | 153 | 2 (1.3) | 39 (25.5) | 112 (73.2) | 14.052 |
| Localized Pca | 264 | 3 (1.1) | 61 (23.1) | 200 (75.8) | 12.689 |
| Metastatic Pca | 97 | 1 (1.0) | 23 (23.7) | 73 (75.3) | 12.887 |
| Gradec | |||||
| Low/Intermediate | 257 | 1 (0.4) | 55 (21.4) | 201 (78.2) | 11.089 |
| High | 104 | 3 (2.9) | 29 (27.9) | 72 (69.2) | 16.826 |
| Control | 195 | 3 (1.5) | 37 (19.0) | 155 (79.5) | 11.026 |
| 950 T/C | |||||
| 950 T/C Genotype (%) | C allele frequency (%) | ||||
| Study group | Total no. | CC | TC | TT | |
| PCaa | 361 | 63 (17.4) | 162 (44.9) | 136 (37.7) | 39.889 |
| Stageb | |||||
| A | 24 | 8 (33.3) | 8 (33.3) | 8 (33.3) | 50 |
| B | 184 | 36 (19.6) | 84 (45.6) | 64 (34.8) | 42.391 |
| C | 56 | 9 (16.0) | 30 (53.6) | 17 (30.4) | 42.857 |
| D | 97 | 11 (10.3) | 39 (41.2) | 47 (48.5) | 30.927 |
| Organ confined PCa | 208 | 44 (21.2) | 92 (44.2) | 72 (34.6) | 43.269 |
| Extraprostatic PCa | 153 | 19 (12.4) | 70 (45.8) | 64 (41.8) | 35.294 |
| Localized Pca | 264 | 53 (20.0) | 122 (46.3) | 89 (33.7) | 43.181 |
| Metastatic Pca | 97 | 11 (10.4) | 39 (41.2) | 47 (48.4) | 30.927 |
| Gradec | |||||
| Low/Intermediate | 257 | 48 (18.7) | 116 (45.1) | 93 (36.2) | 41.245 |
| High | 104 | 15 (14.4) | 46 (44.3) | 43 (41.3) | 36.538 |
| Control | 195 | 29 (14.9) | 98 (50.2) | 68 (34.9) | 40 |
a Prostate cancer versus control, P = 0.939 and 0.294 by the chi-square test for 149 T/C and 950 T/C, respectively.
b According to the Whitmore-Jewett system. Stage A = T1a-bN0M0, Stage B = T1c-2N0M0, Stage C = T3–4N0M0 and Stage D = T1–4N1M0–1 or T1–4N0–1M1. Localized PCa (Stage A + B + C) versus Metastatic PCa (Stage D) P = 0.931 and 0.005 by the chi-square test for 149 T/C and 950T/C, respectively. Organ confined (Stage A + B) versus Extraprostatic PCa (Stage C + D), P = 0.346 and 0.021 by the chi-square test for 149 T/C and 950T/C, respectively.
c Low grade = well-differentiated carcinoma (WHO) or Gleason score 2–4 carcinoma, Intermediate grade = moderately differentiated carcinoma (WHO) or Gleason score 5–7 carcinoma, High grade = poorly differentiated carcinoma (WHO) or Gleason score 8–10 carcinoma. C allele frequency, P = 0.884 and 0.520 by the chi-square test for 149 T/C and 950 T/C, respectively.